Abstract 245P
Background
Dedifferentiated endometrial carcinoma (DDEC) and undifferentiated endometrial carcinoma (UDEC) are uncommon but exhibit aggressive clinical courses. Recent studies reported the loss of expression of SMARCB1 (INI1), SMARCA4 (BRG1), or ARID1A and ARID1B, core or DNA-binding subunits of switch/sucrose non-fermenting (SWI/SNF) complex, resulted in inactivation of SWI/SNF complex that was related to dedifferentiation of endometrial carcinoma.
The efficacy of platinum-based chemotherapy that is standard care for differentiated endometrial carcinoma is still unknown for UDEC and DDEC.
Methods
Thirteen patients diagnosed with UDEC or DDEC at our institute between 1999 and 2019 were included in this retrospective study. Inactivation of SWI/SNF complex was defined as deficiencies in expression of either INI1, BRG1, or ARID1A and ARID1B. Mismatch repair (MMR) status was also confirmed by immunohistochemistry. We evaluated clinical features and outcome in UDEC and DDEC.
Results
The median age at diagnosis was 54 years (range, 47-61). 2/5/6 patients presented with stage I/III/IV disease, respectively. Loss of INI1/BRG1/ARID1A and ARID1B was observed in 1/5/8 patients. Of the 11 patients whose MMR status were evaluated, 9 (82%) were identified as MMR deficient. Two patients underwent surgery alone because of early stage. Three patients received platinum-based chemotherapy as adjuvant therapy, and none of them has relapsed. Of the 8 patients who were unresectable or incompletely resected, 3 patients received platinum-based chemotherapy (doxorubicin/cisplatin or paclitaxel/carboplatin), 4 patients did not due to poor PS, and 1 patient did other regimen. In patients with unresectable or incompletely resected disease with platinum-based chemotherapy, response rate (RR), median progression free survival, and median overall survival (mOS) were 100%, 9.1 months, and 18.6 months, respectively. In patients with unresectable or incompletely resected disease without platinum-based chemotherapy, mOS was 2.7 months.
Conclusions
Platinum-based chemotherapy showed high RR for UDEC and DDEC. We will report case presentation about a few cases with specific clinical courses.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
61P - Clinical implication of BRCA mutation in breast cancer with central nervous system metastasis
Presenter: Jwa Hoon Kim
Session: e-Poster Display Session
62P - IGF axis in breast cancer recurrence and metastasis
Presenter: Hajara Akhter
Session: e-Poster Display Session
63P - Butterfly pea (<italic>Clitoria ternatea</italic> Linn.) flower extract prevents MCF-7 HER2-positive breast cancer cell metastasis in-vitro
Presenter: Azzahra Asysyifa
Session: e-Poster Display Session
64P - Pre-treatment absolute white blood cell profile count as metastatic predictive factors in invasive ductal carcinoma breast cancer
Presenter: Wikania I Gede
Session: e-Poster Display Session
65P - The new mouse anti-nNav1.5 monoclonal antibody
Presenter: Nur Aishah Sharudin
Session: e-Poster Display Session
66P - The TILs near solid structures is a potential prognostic factor of distant metastases in the luminal HER2-negative breast cancer
Presenter: Vladimir Alifanov
Session: e-Poster Display Session
73P - Selinexor in combination with carboplatin and pemetrexed (CP) in patients with advanced or metastatic solid tumors: Results of an open label, single-center, multi-arm phase Ib study
Presenter: Kyaw Thein
Session: e-Poster Display Session
74P - Comprehensive transcriptome analysis of endoplasmic reticulum stress in osteosarcomas
Presenter: Yoshiyuki Suehara
Session: e-Poster Display Session
75P - The evaluation of selective sensitivity of EZH2 inhibitors based on synthetic lethality in ARID1A-deficient gastric cancer
Presenter: Leo Yamada
Session: e-Poster Display Session
76P - Targeted tumour photoImmunotherapy against triple-negative breast cancer therapy
Presenter: Vivek Raju
Session: e-Poster Display Session